
The Algorithmic Illusion: Why AI-Driven Clinical Trials and GLP-1 Setbacks Signal a Market Reckoning
The integration of AI-driven CRISPR therapies and the recent setbacks of GLP-1 drugs in Alzheimer's trials signal a defining inflection point in biome...
Read Full Story →





